Roles and regulation of membrane-associated serine proteases by Qiu, Deyi et al.
New Approaches for Elucidating Protease Biology and Therapeutic Opportunities 583
Roles and regulation of membrane-associated
serine proteases
D. Qiu, K. Owen, K. Gray, R. Bass and V. Ellis1
Biomedical Research Centre, School of Biological Sciences, University of East Anglia, Norwich NR4 7TJ, U.K.
Abstract
Pericellular proteolytic activity affects many aspects of cellular behaviour, via mechanisms involving
processing of the extracellular matrix, growth factors and receptors. The serine proteases have exquisitely
sensitive regulatory mechanisms in this setting, involving both receptor-bound and transmembrane
proteases. Receptor-bound proteases are exempliﬁed by the uPA (urokinase plasminogen activator)/uPAR
(uPAR receptor) plasminogen activation system. The mechanisms initiating the activity of this proteolytic
system on the cell surface, a critical regulatory point, are poorly understood. We have found that the
expression of the TTSP (type II transmembrane serine protease) matriptase is highly regulated in leucocytes,
and correlates with the presence of active uPA on their surface. Using siRNA (small interfering RNA), we
have demonstrated that matriptase speciﬁcally activates uPAR-associated pro-uPA. The uPA/uPAR system
has been implicated in the activation of the plasminogen-related growth factor HGF (hepatocyte growth
factor). However, we ﬁnd no evidence for this, but instead that HGF can be activated by both matriptase
and the related TTSP hepsin in puriﬁed systems. Hepsin is of particular interest, as the proteolytic cleavage
sequence of HGF is an ‘ideal substrate’ for hepsin and membrane-associated hepsin activates HGF with high
efﬁciency. Both of these TTSPs can be activated autocatalytically at the cell surface, an unusual mechanism
among the serine proteases. Therefore these TTSPs have the capacity to be true upstream initiators of
proteolytic activity with subsequent downstream effects on cell behaviour.
Introduction
Pericellular and membrane-associated proteases are involved
in regulating cell behaviour both in normal physiology
and development and in a wide variety of pathologies,
encompassing all the major degenerative diseases, including
cancer, atherosclerosis, arthritis and neurodegeneration. In
many of these, the proteases are involved in either initiation
or progression of the disease and represent potential
therapeutic targets. The well-publicized failure of relatively
broad-specificity synthetic inhibitors of MMPs (matrix
metalloproteinases) in Phase III clinical trials of advanced
cancer has clearly dampened enthusiasm for proteases in
general as therapeutic targets. However, it has also made it
clear that a much more comprehensive understanding of the
basic biology and biochemistry of these and other proteases
is necessary to identify valid targets and discriminate them
from anti-targets, i.e. those proteases that have beneficial
effects. One powerful approach being adopted to address
these issues is the use of proteomic screening to identify both
direct and downstream substrates of individual proteases
[1,2]. An alternative, more targeted, approach is to identify
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the proteases that are responsible for known proteolytic
events using biochemical and enzyme kinetic approaches.
Membrane-associated proteases influence cell behaviour
by essentially two fundamental mechanisms [3–5]. First, by
proteolytic modification of the ECM (extracellular mat-
rix) influencing communication between the cell and its
surrounding matrix environment and, secondly, by the
proteolytic activation of latent growth factors, cytokines
and hormones. The proteases involved in these processes
are not limited to a single mechanistic class, with the best
studied examples belonging to the SP (serine protease)
and metalloproteinase families. The membrane association
of these proteases can either be a consequence of soluble
proteases binding to specific binding sites or receptors on
the plasma membrane, as exemplified by the uPA (urokinase
plasminogen activator)/uPAR (uPA receptor) system of plas-
minogen activation, or by the anchorage of true transmem-
brane enzymes, for example, theMT-MMPs (membrane-type
MMPs) and the ADAM (a disintegrin and metalloproteinase)
family of metalloproteinases. In recent years an unexpected
subfamily of SPs withmembrane-anchorage has emerged, the
TTSPs (type II transmembrane SPs) [6,7].
In this article, we briefly review a number of recent
advances in our understanding of the regulation of the
activity of the uPA/uPAR system, its functional connection
withmembers of the TTSP family and roles of these proteases
in the activation of latent growth factors and the regulation
of protease cascades.
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Regulation of uPA/uPAR activity by
tetraspanins and integrins
The GPI (glycosylphosphatidylinositol)-anchored protein
uPARbinds uPAwith high affinity (Kd of approx. 0.1 nM) via
the N-terminal EGF (epidermal growth factor)-like domain
of uPA. The crystal structure of uPAR has recently been
solved independently by several groups, both in complexwith
a peptidomimetic antagonist [8] and theN-terminal fragment
of uPA [9]. These studies appear to confirm predictions from
biochemical and enzymological studies that the catalytic do-
mainof uPA is not involved inor affectedby receptor binding,
and that uPAR has no direct cofactor effect on the activity of
uPA [10,11]. Nevertheless, binding of uPA to uPAR on the
cell surface greatly enhances plasminogen activation, both in
cell culture systems [12–14] and in in vivo models [15–17].
The interaction between uPA and uPAR is therefore critical
for the generation of pericellular plasmin activity. If the
function of the uPA/uPAR system is to generate proteolytic
activity to modify the ECM, it might be expected that it
communicates with the systems involved in cell adhesion and
there has beenmuch interest in potential interactions between
uPAR and integrins, the major class of cell-adhesion recept-
ors. In various cell types, uPAR has been shown to associate
with different integrins, and, in some cases, tomodulate integ-
rin function (reviewed in [18]).Modulation of uPAR function
by cell-adhesion systems is an equally intriguing prospect.
We have shown that expression of CD82, a member of the
tetraspanin family of transmembrane proteins, profoundly
affects uPAR-dependent plasminogen activation. Tetraspan-
ins have roles in organizing cell-adhesion molecules on the
cell surface by direct interactions with integrins and other tet-
raspanins, to form large multimeric complexes. Transfection
of normal breast epithelial cells withCD82, a tetraspaninwith
metastasis-suppressing activity, has no effect on the expres-
sion of uPA, uPAR or other components of the plasminogen
activation system, but nevertheless causes a 50-fold reduction
in plasminogen activation [19]. This reduction was shown to
be due to uPAR losing its ability to bind uPA in the presence
of CD82, despite no covalent alterations in the receptor, e.g.
proteolysis. Therefore, in these cells, the presence of CD82
renders uPAR ‘cryptic’, and may provide a novel mechanism
for dynamically down-regulating the activity of this system.
Surprisingly, CD82 and uPAR did not co-localize on the
cell surface, although uPAR was found to be redistributed
to focal adhesions by CD82 where it co-localized with the
integrin α5β1, and uPAR and α5β1 could be co-immunopre-
cipitated under these conditions. This led to the hypothesis
that an interaction with α5β1 was responsible for the altered
behaviour of uPAR and subsequent effects on plasminogen
activation [19].
We have used cell lines transfected with the α5 integrin
subunit to confirm that it does influence uPAR-mediated
plasminogen activation, but have been unable to demonstrate
a physical interaction between uPAR and α5β1 using soluble
recombinant proteins (R. Bass and V. Ellis, unpublished
work). Although this observation does not exclude the exist-
ence of interactions on the cell surface, where they could be
promoted by proximity effects, they do hamper attempts to
define themechanism involved. The various crystal structures
of uPAR suggest that there is significant conformational
mobility between its three constituent domains, all of which
co-operate to form the ligand-binding cavity [8,9]. Therefore
it could be postulated that interactionwith an partner protein,
such as α5β1, alters the conformational relationship between
the three uPAR domains such that uPA binding is abolished,
as we observe in the presence of CD82.
Initiation of uPAR-mediated plasminogen
activation
uPAR-mediated plasminogen activation is inherently effi-
cient due to the amplification of proteolytic activity resulting
from reciprocal zymogen activation. In this feedback activ-
ation process, any amount of plasmin initially generated can
activate the zymogenic pro-uPA form, leading to further plas-
min generation and subsequent amplification. However, the
source of the proteolytic activity responsible for initiating this
process is a matter of controversy. Essentially two mechan-
isms are possible, one involving only the proteolytic activities
of uPA and/or plasmin, the other requiring an exogenous
protease to activate pro-uPA. In model systems, the very low
intrinsic activity of pro-uPA is sufficient to efficiently initiate
plasminogen activation, but only in kinetically favourable
situations where the apparent Km for plasminogen activation
is lowered, such as the cell surface [20]. However, although
plasmin can efficiently activate pro-uPA, there is little
specificity in this activation, and in vitromanyother proteases
with trypsin-like activity can activate pro-uPA. Initiation of
plasminogen activation by this relatively non-specific mech-
anism seems unlikely, given the potentially wide-ranging
downstream consequences. Nevertheless it is possible that
in specific situations, other proteases do have a role in the
initiation of uPAR-mediated plasminogen activation.
Strong evidence that this could be an importantmechanism
came from our comparison of two closely related, uPAR-
expressing, monocytic cell lines. In the presence of pro-uPA,
U937 cells accumulated pro-uPA on their surface, whereas
THP-1 cells accumulated active uPA, suggesting constitutive
activation of pro-uPA on the latter [21,22]. This activity was
shown to be specific for uPAR-bound pro-uPA, with no
activation detected in the conditioned medium; the activating
protease was associated with the plasma membrane and
appeared to be constitutively active. These characteristics
are close to ideal for a specific initiation mechanism. The
protease responsible for pro-uPA activation on THP-1 cells
was identified as the TTSP matriptase [21].
TTSPs
SPs are historically the most well-studied family of proteo-
lytic enzymes, so it came as some surprise when the presence
of a previously unsuspected subfamily was identified, char-
acterized by the presence of an N-terminal transmembrane
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Figure 1 TTSP domain structures
The unique modular structures of the TTSPs discussed are shown, using the following module name abbreviations: SEA, SEA
(sea urchin sperm protein, enteropeptidase, agrin) domain; CUB, CUB [complement, UEGF (urchin embryonic growth factor),
BMP-1 (bone morphogenetic protein 1)] domain; LA, LDL (low–density lipoprotein) receptor type-A repeat; MAM, MAM
(meprin, A5, protein phosphatase mu) domain; SR, Group A scavenger receptor domain; Ser Pr, serine protease domain.
Each of the TTSPs has a short cytoplasmic tail of typically 20–50 residues, although some extend to 160 residues, and are
likely to play a role in targeting the proteases to discrete membrane localizations.
extension [6]. The TTSPs, estimated to contain more than
20 human members, are mosaic proteins in common with
the soluble proteases of the plasminogen activation, blood
coagulation and complement systems. However, they utilize
a completely distinct set of protein modules in their assembly
(Figure 1), including some known to be protein–protein
interaction domains in other proteins [6,7]. The majority
of these proteases have yet to have their biological function
and potential substrates identified. Interestingly, the family
includes enteropeptidase, the existence of which was first
demonstrated by Pavlov over 100 years ago, and known for
many years as the highly specific activator of trypsinogen,
but only recently characterized as a transmembrane protein
[23,24]. Other TTSPs with known physiological roles are
corin and TMPRSS3. Corin activates the cardiac hormone
atrial natriuretic peptide and is involved in blood pressure
regulation [25], and mutations in TMPRSS3 are associated
with congenital deafness, although themechanism involved is
unknown [26].
Two of the most interesting TTSP family members in
terms of pathology are matriptase and hepsin, both of which
are up-regulated in a variety of cancers and correlate closely
with disease progression [27]. Hepsin is among the smallest
of the TTSPs, containing only one additional protein module
(Figure 1), and the first to be cloned [28]. Mice with targeted
deletion of the hepsin gene display no overt phenotypic
abnormalities [29]. Overexpression of hepsin in prostatic
epithelium of transgenic mice leads to disruption of basement
membrane, and promotes disease progression in a model of
prostate cancer [30]. Matriptase-deficient mice develop nor-
mally, but do not survive postnatally owing to an epidermal
barrier defect [31]. Transgenic mice with a very modest over-
expression of matriptase in the skin become remarkably sus-
ceptible to carcinogen-induced tumour formation [32]. The
molecular targets of hepsin and matriptase leading to these
effects on tumour initiation and progression have yet to be
identified.
Proteolytic activation of HGF (hepatocyte
growth factor)/SF (scatter factor)
HGF/SF is one of two growth factors closely related to plas-
minogen. Both have mutations in the catalytic triad residues,
rendering them inactive as enzymes, but retain the canonical
proteolytic activation site of the SPs. Cleavage at this site is an
absolute requirement for activation of the cognate receptor,
which, in the case of HGF/SF, is the proto-oncogene c-Met
[33], making this a key step in the regulation of the c-Met
signalling pathway.
uPAhas been proposed to be an efficient activator ofHGF/
SF [34–36]. However, despite the similarity of HGF/SF and
plasminogen, the proteolytic activation sequences are dissim-
ilar, and uPA is known to be an extremely specific protease. In
our own laboratory,we have been unable to corroborate these
findings (K. Owen and V. Ellis, unpublished work), leading
us to investigate other potential pericellular activators. In
biochemical studies, both matriptase [37] and hepsin [38,39]
have been shown to activate HGF/SF. Our own quantitative
data show that matriptase is the most efficient of the known
HGF/SF activators, with hepsin having approx. 10% relative
activity and both being at least three orders of magnitude
more efficient than uPA (K. Owen and V. Ellis, unpublished
work). These studies utilized truncated soluble forms of the
proteases, but, using both siRNA (small interfering RNA)
and overexpression approaches, we have also demonstrated
that the transmembrane forms of both proteases efficiently
process HGF/SF to its biologically active form (D. Qiu, K.
Owen and V. Ellis, unpublished work). Although this has yet
be demonstrated in vivo, it may provide a mechanism for the
involvement of these TTSPs in the development of cancer. At
the biochemical level, it remains to be determined whether
membrane localization of the proteases confers them with
any kinetic advantage and whether their N-terminal domains
are involved in substrate recognition of HGF/SF by exosite
interactions.
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A general role for TTSPs as initiators of
protease cascades?
Our observation that matriptase can activate uPAR-bound
pro-uPA, and therefore the plasminogen activation cascade,
raises the question of whether matriptase, and potentially
other TTSPs, could have a more general role in the initiation
of protease cascades. An observation that supports this
hypothesis is the demonstration thatmatriptase is responsible
for the activation of a previously unsuspected protease
cascade. The epidermal defect observed in matriptase-null
mice [31] is due to an inability to process the keratinocyte
polyprotein filaggrin in the absence of matriptase [40].
However, although profilaggrin was assumed to be a direct
substrate for matriptase, mice deficient in prostasin, a GPI-
anchored SP, were subsequently found to have a similar
phenotype and lack of filaggrin processing [41]. One inter-
pretation of the observation that both proteases are necessary
is that they form part of the same proteolytic cascade. Both
biochemical and genetic studies demonstrate this to be the
case, with matriptase responsible for activating prostasin
[42]. A very interesting feature of matriptase that further
supports this hypothesis is that it has the ability to undergo
autocatalytic activation [43,44]. Themajority of SP zymogens
are unable to do this, i.e. the sequence of their proteolytic
activation sites do not match the substrate specificity of their
active site, and zymogen activation requires an upstream
activating protease or other mechanism. Although the TTSPs
as a family have not been studied in detail, it is nevertheless
significant that several of those that have been studied can
be autoactivated in vitro. In addition to matriptase, its close
homologues matriptase-2 [45] and matriptase-3 [46], TM-
PRSS2 [47] and TMPRSS3 [26] have all been demonstrated
to autoactivate when expressed as truncated soluble proteins,
and hepsin also when expressed in its transmembrane form
(D. Qiu and V. Ellis, unpublished work). Although this
critical characteristic in most cases needs to be demonstrated
more rigorously, these observations clearly point to many of
the TTSPs having an ability not common among the highly
regulated multidomain SPs. Therefore, as with matriptase,
they could act as true initiators of proteolytic cascades.
It is worth mentioning that enteropeptidase, although the
initiating protease of the digestive cascade, does not undergo
autoactivation and needs to be activated by trypsin.
Although the autoactivation of these TTSPs can be readily
detected in vitro, it appears unlikely that it would not be a
highly regulated process in vivo. As these are transmembrane
proteins, it could be envisaged that a potential mechanism for
its regulation could be membrane localization and clustering.
Another important consideration is the potential role of the
accessory extracellular domains of these proteins. If these are
involved in homotypic protein–protein interactions, auto-
activation could be facilitated. There is some evidence for
this, as several disease-associatedmutations in theN-terminal
domains of TMPRSS3 inhibit its activation [26], and both
point and deletion mutations in the N-terminal domains of
matriptase have the same effect [44]. The interpretation of the
observations with matriptase is not straightforward, as they
may be due to an impaired interaction of matriptase with its
physiological inhibitor, the Kunitz-family member HAI-1
(HGF activator inhibitor-1), which has been proposed to
be involved in the activation of matriptase in some cell cul-
ture models [44]. Although much needs to be learned
regarding the regulation of autoactivation, it has been clearly
demonstrated that HAI-1 is not necessary for matriptase
activation, either in vivo [48] or in the in vitro activation of
pro-uPA by leucocytes [21].
Conclusions
The regulation of proteolytic activity at the cell surface is
clearly complex, as befits its key role in dictating cellular beha-
viour. Recent evidence has highlighted unexpected complex-
ity in the functional regulation of the pericellular plasminogen
activation system, which can be influenced by components of
the cell-adhesion machinery. The TTSP matriptase also has
a potential role by initiation of the plasminogen-activation
cascade. An argument has been made here for a more gene-
ral role of the TTSPs in initiating protease cascades, although
they can clearly also have direct effects, such as in the pro-
teolytic activation ofHGF/SF. The TTSPs, in particular those
that are highly up-regulated in cancer, such as matriptase and
hepsin, represent exciting future therapeutic opportunities,
as evidence accumulates that they may have functional roles
in disease development and progression. However, it is clear
that, before then, much more needs to be known about the
activities, natural substrates and functional regulation of
these proteases in biochemical and cellular studies as well as
their physiological roles in animal models.
The work described here from our laboratory was supported by
grants and research fellowships from the British Heart Foundation,
with additional support from the Norfolk and Norwich Big C Appeal.
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